Sverige - svensk - Läkemedelsverket (Medical Products Agency)

orifarm ab - hydroxikarbamid - kapsel, hård - 500 mg - natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne; sojalecitin hjälpämne; hydroxikarbamid 500 mg aktiv substans - hydroxikarbamid

Sverige - svensk - Läkemedelsverket (Medical Products Agency)

orifarm generics a/s - hydroxikarbamid - kapsel, hård - 500 mg - laktosmonohydrat hjälpämne; hydroxikarbamid 500 mg aktiv substans

Sverige - svensk - Läkemedelsverket (Medical Products Agency)

orifarm ab - hydroxikarbamid - kapsel, hård - 500 mg - natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne; sojalecitin hjälpämne; hydroxikarbamid 500 mg aktiv substans

Den Europæiske Union - svensk - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anemi, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Den Europæiske Union - svensk - EMA (European Medicines Agency)

pfizer europe ma eeig  - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

Den Europæiske Union - svensk - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - ropeginterferon alfa-2b - polycytemia vera - immunstimulatorer, - besremi är indicerat som monoterapi hos vuxna för behandling av polycytemi vera utan symtomatisk splenomegali.

Sverige - svensk - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - kalciumfolinat hydrat - injektionsvätska, lösning - 10 mg/ml - kalciumfolinat hydrat 12,7 mg aktiv substans - kalciumfolinat

Sverige - svensk - Läkemedelsverket (Medical Products Agency)

medac gesellschaft für klinische spezialpräparate mbh - dinatriumlevofolinat - injektions-/infusionsvätska, lösning - 50 mg/ml - dinatriumlevofolinat 54,65 mg aktiv substans - medel mot toxicitet vid cytostatikabehandling

Den Europæiske Union - svensk - EMA (European Medicines Agency)

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastiska medel - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.

Den Europæiske Union - svensk - EMA (European Medicines Agency)

novartis europharm limited - ruxolitinib (som fosfat) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastiska medel - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycytemi vera (pv)jakavi är indicerat för behandling av vuxna patienter med polycytemi vera som är resistenta eller intoleranta av hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.